89bio, Inc. (NasdaqGM: ETNB)
Health Care · Biotechnology · US
$—
— today · — 1Y
89bio, Inc. (NasdaqGM: ETNB) operates in the Biotechnology industry within the Health Care sector.
trading between 7.84 and 15.06.
Tweenvest scores 89bio, Inc. across four factors: quality 27/100. Its strongest factor is quality.
ETNB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.41
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $15.06
- 52-week low
- $7.84
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 93
- Next earnings
- —
About 89bio, Inc.
Operating as a clinical-stage biopharmaceutical company, 89bio, Inc. is dedicated to advancing and commercializing therapeutic solutions for ailments impacting the liver and metabolic system. Their flagship product candidate, pegozafermin, is a modified fibroblast growth factor 21 (FGF21) analog specifically designed to address nonalcoholic steatohepatitis (NASH). Furthermore, the company has plans to explore pegozafermin's utility in treating severe hypertriglyceridemia. Founded in 2018, 89bio, Inc. maintains its corporate headquarters in San Francisco, California.
- ISIN
- US2825591033
- Founded
- 2018
- Listed since
- Nov 11, 2019
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.53 | -1.60% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $439.02 | -0.73% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.48 | -0.87% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $547.02 | -1.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $825.08 | -1.02% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $150.71 | -5.11% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.